Jazz Pharmaceuticals Posts 19% Revenue Growth, Eyes Zanidatamab Approval
Event summary
- Jazz Pharmaceuticals reported $1.1 billion in total revenues for Q1 2026, up 19% YoY.
- Xywav sales grew 18% YoY to $408 million with 425 net patient adds.
- Zanidatamab sBLA for HER2+ 1L GEA received FDA Priority Review with PDUFA date of August 25, 2026.
- Company reaffirmed 2026 revenue guidance of $4.25B–$4.5B.
- Generated $408 million in cash from operations and $200 million from PRV sale.
The big picture
Jazz Pharmaceuticals' strong Q1 2026 performance highlights its ability to drive growth across multiple franchises, particularly in sleep disorders and oncology. The pending FDA decision on zanidatamab represents a significant strategic inflection point, potentially expanding its oncology portfolio. The company's disciplined financial management and pipeline advancements position it for long-term durable growth in the competitive biopharmaceutical landscape.
What we're watching
- Regulatory Milestones
- Whether zanidatamab receives FDA approval by August 25, 2026, and its potential market impact.
- Commercial Execution
- The pace at which Xywav and Epidiolex can sustain growth amid competitive pressures.
- Pipeline Progress
- How Phase 3 ACTION trial results for Modeyso will affect its commercial prospects.
Related topics